GC Biopharma said it has signed a co-development agreement with Kanaph Therapeutics for a bispecific antibody-drug conjugate (ADC) therapy.

The agreement includes an option-based collaboration framework, allowing GC Biopharma to join the development upon meeting agreed milestones for the bispecific ADC candidate currently under development by Kanaph Therapeutics. Specific details of the agreement, such as target indications, option conditions, and total contract size, were not disclosed.

The bispecific ADC is designed to target markers expressed in a variety of solid tumors. It holds the potential to address a broad patient population and overcome drug resistance in existing cancer treatments, highlighting its strong market potential.

"GC Biopharma continues to increase investments in the development of treatments for cancer and immune disorders,” GC Biopharma Head of R&D Jeong Jae-uk said. “This strategic collaboration with Kanaph Therapeutics marks a crucial step toward the development of innovative therapies in the oncology market, where there is a significant unmet medical need."

“Our bispecific ADC aims to provide a novel therapeutic option for cancer patients suffering from drug resistance and adverse effects,” Kanaph Therapeutics CEO Lee Byoung-chul said. “By leveraging GC Biopharma's extensive experience in new drug development, we expect to expedite the timeline for delivering this breakthrough treatment."